ApoA-I technology is recognized for its ability to transform the treatment
of cardiovascular disease
TSX Exchange Symbol: RVX
CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that the World Economic Forum has selected Resverlogix as a winner of the very prestigious Technology Pioneer Award in recognition of its NexVas(TM) Plaque Removal program. Candidates for this award must be involved in the development of life-changing technologies and have potential for long-term impact on business and society.
"We are elated to receive this high-level recognition from such an important leading global body as the World Economic Forum. This awareness that our innovative technology could have such a dramatic positive impact for society, as it relates to the future treatment of cardiovascular disease (CVD), further validates the positive direction of our NexVas technology," stated Mr. Donald McCaffrey, President, CEO & Co-Founder of Resverlogix.
Resverlogix was selected because it is developing exceptionally promising new molecules that increase the production of ApoA-l and high density lipoprotein (HDL) for the treatment of atherosclerosis. According to the World Health Organization, CVD is the number one cause of death globally, an immense problem currently responsible for killing nearly 18 million people annually worldwide.
"I would like to offer Canada's sincere congratulations to Resverlogix for winning this international award from the World Economic Forum," said the Honourable Minister Jim Prentice, Minister of Industry. "Resverlogix is doing some incredible work in advancing the treatment of atherosclerosis, the major underlying cause of cardiovascular disease and this award is a testament to Canada's world-class biopharmaceutical industry."
Dr. Norman Wong, M.D., Co-Founder of Resverlogix added, "Current
|SOURCE Resverlogix Corp.|
Copyright©2007 PR Newswire.
All rights reserved